Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | IDH2 | P48735 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28955970 | 1.00 | MALT1 (0.36) | MALT1IDH1IDH2SYKADRB1 | |
| SCHEMBL28955971 | 1.00 | MALT1 (0.36) | MALT1IDH1IDH2SYKADRB1 | |
| SCHEMBL28956217 | 1.00 | MALT1 (0.36) | MALT1IDH1IDH2SYKADRB1 | |
| Tert-Butanol SCHEMBL28823763 | 0.81 | MALT1 (0.41) | MALT1IDH1IDH2SYKADRB1 | |
| SCHEMBL1118377 | 0.81 | MALT1 (0.41) | MALT1IDH1IDH2SYKADRB1 | |
| SCHEMBL31708103 | 0.78 | KDM4E (0.33) | — | |
| SCHEMBL17109750 | 0.77 | MALT1 (0.43) | MALT1IDH1IDH2SYKADRB1 | |
| SCHEMBL28956111 | 0.77 | IDH1 (0.35) | MALT1IDH1IDH2AAK1 | |
| SCHEMBL30307646 | 0.77 | IDH1 (0.35) | MALT1IDH1IDH2AAK1 | |
| SCHEMBL3295825 | 0.74 | MALT1 (0.47) | MALT1IDH1IDH2SYKADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-4143179-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2023-03-08 | — | — | EP | disclosed |
| CN-115551841-A | Azetidin-3-ylcarbinol derivatives as modulators of the CCR6 receptor | 爱杜西亚药品有限公司 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR3 | MALT1 985/4885IDH1 4236/4885IDH2 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.